H.C. Wainwright Has Just Reaffirmed $18.0000 Target Price Per Share on Fennec Pharmaceuticals Inc (FENC) stock, While They’ve Also Reiterated Their “Buy” Rating

June 20, 2018 - By Kristen Paramore

Fennec Pharmaceuticals Inc (FENC) Rating Reaffirmed

EU: In an analyst report revealed to investors on 19 June, H.C. Wainwright restate their “Buy” rating on Fennec Pharmaceuticals Inc (FENC) shares. They now have a $18.0000 target price per share on the company. H.C. Wainwright’s target suggests a potential upside of 64.08 % from the company’s last stock close price.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Ratings Coverage

Among 2 analysts covering Fennec Pharmaceuticals Inc. – Common Stock (FENC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fennec Pharmaceuticals Inc. – Common Stock has $1800 highest and $16 lowest target. $17.50’s average target is 59.53% above currents $10.97 stock price. Fennec Pharmaceuticals Inc. – Common Stock had 5 analyst reports since February 20, 2018 according to SRatingsIntel. On Wednesday, May 23 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright maintained the shares of FENC in report on Tuesday, June 19 with “Buy” rating. The stock of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) has “Buy” rating given on Monday, April 2 by H.C. Wainwright.

The stock increased 0.09% or $0.01 during the last trading session, reaching $10.97. About 42,771 shares traded. Fennec Pharmaceuticals Inc. (FENC) has risen 191.86% since June 20, 2017 and is uptrending. It has outperformed by 179.29% the S&P500.

Analysts await Fennec Pharmaceuticals Inc. (NASDAQ:FENC) to report earnings on August, 10. They expect $-0.10 EPS, up 9.09 % or $0.01 from last year’s $-0.11 per share. After $-0.09 actual EPS reported by Fennec Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 11.11 % negative EPS growth.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. The company has market cap of $203.81 million. The Company’s lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. It currently has negative earnings. The firm was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

More news for Fennec Pharmaceuticals Inc. (NASDAQ:FENC) were recently published by: Nasdaq.com, which released: “Fennec Pharmaceuticals Set to Join Russell 3000 Index” on June 11, 2018. Nasdaq.com‘s article titled: “Fennec Announces Results of Annual Meeting” and published on June 08, 2018 is yet another important article.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: